Translational research using human monoclonal antibody for ovarian cancer peritoneal metastasis
| Project/Area Number |
25893086
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-08-30 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 卵巣癌 / 腹膜転移 / 治療 / トランスレーショナルリサーチ / 分子標的治療 |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to prove the hypothesis that HMOCC-1, an ovarian cancer-specific human monoclonal antibody, inhibits adhesion of MUC16 on the surface of ovarian cancer to MSLN protein on the surface of normal peritoneum. This study revealed that the inhibitory effect of HMOCC-1 antibody against the adhesion of ovarian cancer cells to normal peritoneal cells is not caused through inhibition of binding of MSLN and MUC16, which suggests a possibility that HMOCC-1 antibody may function through the other molecular mechanisms. The study will be required further studies to define the molecular mechanisms of the HMOCC-1 function against ovarian cancer peritoneal metastasis.
|
Report
(3 results)
Research Products
(3 results)
